Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological f...
Guardado en:
Autores principales: | Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki, Shinichi Iwasaki |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/83aafb03d05a4f159e72936107a43a7e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Nobukazu Fujimoto, et al.
Publicado: (2021) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021) -
Nivolumab-Induced Exocrine Pancreatic Insufficiency
por: Boudewijn Sweep, et al.
Publicado: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021) -
Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)